Research progress in transarterial chemoembolization combined with systemic targeted immunotherapy for unresectable hepatocellular carcinoma
10.3969/j.issn.1008-794X.2025.12.002
- VernacularTitle:经动脉化疗栓塞联合系统靶免治疗中晚期肝细胞癌的研究进展
- Author:
Xiaoyang XU
1
;
Jian SHEN
;
Xiaoli ZHU
Author Information
1. 215000 江苏苏州 苏州大学附属第一医院介入科;苏州大学附属第四医院血管外科与介入科
- Keywords:
hepatocellular carcinoma;
transcatheter arterial chemoembolization;
targeted therapy;
immunotherapy;
predictive indicator
- From:
Journal of Interventional Radiology
2025;34(12):1293-1299
- CountryChina
- Language:Chinese
-
Abstract:
With the continuous updates and iterations of molecular targeted drugs and immune checkpoint inhibitors,transcatheter arterial chemoembolization(TACE)combined with systemic targeted immunotherapy has become the main treatment method for unresectable hepatocellular carcinoma(HCC).However,due to the high heterogeneity of HCC,not all patients can get benefit from this combination therapy.In addition,due to the lack of specific prognostic markers,there are significant differences in therapeutic efficacy among individuals.Although various predictive indicators have achieved significant results in predicting the prognosis of HCC patients receiving TACE or targeted immunotherapy,there are few reports on the predictive prognosis of TACE combined with systemic targeted immunotherapy for HCC patients.This article explores the possibility and progress of using predictive indicators in personalized prediction of the prognosis of unresectable HCC patients undergoing TACE combined with targeted immunotherapy.It is expected to provide new ideas for clinical screening of beneficiary populations and improving patient prognosis.
